Full Description
Now in its third edition! Ovarian Carcinoma is an invaluable source of information because it gives a complete overview of all aspects: histologic classification, FIGO staging, tumor markers, symptoms, diagnosis, operative treatment, chemotherapy, radiation therapy, complications such as pregnancy and AIDS, biological response modifiers and the status of clinical trials. The new chapter on biologic response modification is especially noteworthy since it reports on new developments now being tested in clinical trials. All the other chapters have been expanded and updated, too. At the same time, the author has kept his clear, readable style that makes the book easy to understand. The contents are based on actual clinical experience and thus extremely practical.
Contents
1 Introduction.- 2 Anatomy, Embryology, and Comparative Anatomy.- 3 Epidemiology of Cancer of the Ovary.- 4 Histologic Classification of Ovarian Tumors.- 5 Histologic Typing of Ovarian Tumors: Definitions and Discussion.- 6 Histologic, Nuclear, and Stromal Grading.- 7 Symptoms, Signs, and Diagnosis.- 8 Diagnostic Evaluation and Preoperative Work-up.- 9 Preoperative and Postoperative Management.- 10 Diagnosing and Managing the Adnexal Mass.- 11 Staging Ovarian Cancer.- 12 Treatment of the Common Epithelial Cancers.- 13 Managing Ovarian Tumors of Childhood and Adolescence.- 14 Ovarian Cancer Complicating Pregnancy.- 15 Low Malignant Potential Ovarian Tumors: Borderline Ovarian Tumors.- 16 Postmenopausal Palpable Ovary Syndrome.- 17 Surgical Treatment of Cancer of the Ovary: Technique.- 18 Recurrent Cancer of the Ovary: Surgical Treatment.- 19 Second Look Operation.- 20 Role of Radioactive Isotopes in Management of Ovarian Cancer.- 21 Role of Chemotherapy in Ovarian Cancer.- 22 Platinum Drugs.- 23 Role of Radiation Therapy in Management of Ovarian Cancer.- 24 Autoimmune and Immunodeficiency Diseases.- 25 Tumor Markers in Ovarian Cancer.- 26 Sex Steriod Receptors.- 27 Biologic Response Modification.- 28 Immunotherapy and Immunopotentiation.- 29 Directions in the Design of Clinical Trials, Present and Future.- Addendum.
